HWN Suggests

How the ASCVD Risk Calculator Guides Smart Prevention

Many adults carry silent cardiovascular risks. The ASCVD tool offers a common-sense approach to risk prediction, especially for people aged 40–79. However, this calculator serves as a starting point, not the full picture. It doesn’t account for triglycerides, apoB, insulin resistance, or family history. So while it’s helpful, smart prevention looks deeper. A one-size-fits-all score cannot capture your personal journey. Some patients carry multiple mild risk factors—each small alone but meaningful together. Others show hidden danger only through specialized tests.

read full article

Featured

 Heart Risk Calculator Often Overestimates Danger, Study Finds

Doctors use the ASCVD calculator to decide if someone should take statins. But if the tool isn’t accurate, patients could be taking medication they don’t need. This study suggests we should be cautious about relying too much on risk scores alone—especially for those without diabetes and those from diverse backgrounds. Doctors often use a tool called the ASCVD (Atherosclerotic Cardiovascular Disease) Risk Calculator to estimate a person’s chance of having a heart attack or stroke. But this study shows that the calculator may be overestimating that risk—sometimes by a lot—especially for people without diabetes. That means many people may be prescribed statins when they might not need them.

 Patients find CAC more persuasive than ASCVD risk score for statin decisions

Patients who received a protocol-driven recommendation to initiate statin therapy for primary prevention of cardiovascular disease based upon their CT angiography coronary artery calcium score were twice as likely to actually start on the drug than those whose recommendation was guided by the American College of Cardiology/American Heart Association Pooled Cohort Equations Risk Calculator, according to the results of the randomized CorCal Vanguard study.

Articles of Interest

Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Real-World Population

In sum, as recently recommended, we conducted a critical evaluation of the ASCVD Pooled Cohort risk equation from a relevant large, diverse, “real-world” target population, overall and in key understudied subgroups. We found that this risk equation substantially overestimated actual ASCVD risk in adults not treated with statin therapy for primary prevention without diabetes (overall and across all sociodemographic subgroups), and demonstrated suboptimal accuracy in those with or without diabetes.

Estimated Atherosclerotic Cardiovascular Disease Risk Score: An Automated Decision Aid for Statin Therapy

Estimation of atherosclerotic cardiovascular disease (ASCVD) risk is a key step in cardiovascular disease (CVD) prevention, but it requires entering additional risk factor information into a computer. We developed a simplified ASCVD risk score that can be automatically calculated by the clinical laboratory when a fasting standard lipid panel is reported.

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort

As recommended by the American Heart Association, an external validation study of the ACC/AHA ASCVD cardiovascular risk score was carried out to assess its diagnostic performance in a population not included in the original model. It is the first study carried out on a Latin American population. The score is calibrated, and its discrimination is good across the cardiovascular risk spectrum in a primary care setting. This model has operational characteristics that favor the use of the estimation of cardiovascular risk for the next ten years in the population studied.

Gauging ASCVD Risk, Does Race Matter?∗

However, commonly used ASCVD risk estimation schemes to guide long-term clinical decisions are nonetheless derived and validated primarily in Caucasian and African American populations, and their relevance to other ethnic groups has been questioned. For instance, the ACC/AHA ASCVD score tends to underestimate the risk in certain race-ethnic groups such as American Indians and some Hispanics, and overestimates the risk in Asian populations.

Is it useful to calculate the Atherosclerotic Cardiovascular Disease (ASCVD) score in a patient taking a statin (HMG-CoA reductase inhibitor)?

Calculating the ASCVD score can help clinicians make informed decisions about statin therapy intensity and the potential need for additional treatments. The score can also be used to monitor changes in cardiovascular risk over time and adjust treatment accordingly. By considering the ASCVD score and other risk factors, clinicians can provide personalized care and improve patient outcomes.

Is the Atherosclerotic Cardiovascular Disease (ASCVD) risk score useful in secondary prevention cases?

The reason the ASCVD risk score doesn't apply to these patients is that it was developed using data from individuals without prior cardiovascular events, and its predictive value is only validated for primary prevention.

Nearly Half of All Heart Attacks May Be Missed by Current Screening Tools

Current medical screening techniques could be failing to catch nearly half of those who experience a heart attack, according to new research, suggesting many of the millions of heart attacks that happen each year could be prevented with improved methods. In the US, heart attack risk is typically assessed according to a set of criteria such as an atherosclerotic cardiovascular disease (ASCVD) score, which measures factors linked to the development of cardiovascular disease. Patients are then monitored or treated if their scores exceed a certain threshold.

Power of the Pedigree: The Family History Variable for ASCVD Risk Stratification

Risk assessment in primary ASCVD prevention seeks to identify patients who are more likely to benefit from pharmacologic interventions. This assessment includes genetic predisposition, social habits, and environmental factors that increase a patient's vulnerability to the development of disease. The presence of a FamHx of premature ASCVD should prompt the investigation and more aggressive management of other risk factors such as hypertension, dyslipidemia, and diabetes.

Strengths and Weakness of ASCVD Risk Calculation: A Qualitative Study

The PCE ASCVD risk calculator was seen as most useful in facilitating discussions regarding behavior and lifestyle changes, suggesting the potential benefit of incorporating variables related to patients' health behaviors in a revised model. The new PREVENT equations provide a helpful first step by removing race and including social determinants. The next step may be to add health behaviors and visual images to facilitate patient counseling and comprehensio

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Elevated Lp(a) may be particularly important in asymptomatic people with CAC levels ≥ 100, a new MESA analysis suggests.

Why is Atherosclerotic Cardiovascular Disease Risk Overestimated by the ACC/AHA Pooled Cohort Equation?

Changing trends in statin use, revascularization, and underascertainment of events failed to explain the overestimation of ASCVD risk by the ACC/AHA risk prediction model. Further efforts are needed to recalibrate the model using contemporary data to ensure optimal guidance in ASCVD risk reduction recommendations.

Resources

ASCVD Risk Calculator (PCE 2013)

Pooled Cohort Equations (PCE) risk predicts 10-year risk for a first atherosclerotic cardiovascular disease (ASCVD) event.